In vivo tau imaging: Obstacles and progress
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning from the battlefield. The considerable evidence pointing at the accumulation of tau aggregates and its recognition as a risk factor in neurodegenerative conditions such as Alzheimer's disease have led to a major effort to develop selective tau ligands that would allow research into the physiopathologic underpinnings of traumatic brain injury and chronic traumatic encephalopathy in military personnel and the civilian population. These tracers will allow new insights into tau pathology in the human brain, facilitating research into causes, diagnosis, and treatment of traumatic encephalopathy and major neurodegenerative dementias, such as Alzheimer's disease and some variants of frontotemporal lobar degeneration, in which tau plays a role. The field of selective tau imaging has to overcome several obstacles, some of them associated with the idiosyncrasies of tau aggregation and others related to radiotracer design. A worldwide effort has focused on the development of imaging agents that will allow selective tau imaging in vivo. Recent progress in the development of these tracers is enabling the noninvasive assessment of the extent of tau pathology in the brain, eventually allowing the quantification of changes in tau pathology over time and its relation to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy and patient recruitment for antitau therapeutic trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“[3] Lee VM, Goedert M, Trojanowski JQ.”
Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury
McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E., Budson, A. E., Santini, V. E., Lee, H.-S., Kubilus, C. A., & Stern, R. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a9d503 · Cited by 2,295 · cited 3×
“[4] McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al.”
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“[43] Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al.”
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“Although the prevalent etiologic hypothesis for AD postulates that either misprocessing of the amyloid precursor protein or disruption of its clearance leads to the accumulation of Ab in the brain in the form of plaques [26], human postmortem studies have shown that it is the density of NFTs and not of Ab insoluble pl…”
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225 · cited 1×
“[36] Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al.”
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 1×
“[124] Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al.”
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Self-citationNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Self-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 1×
“[37] Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C,”
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 2×
“3) First-in-human (18)F-T807 PET studies in AD patients, MCI, and healthy participants have shown that cortical (18)F-T807 retention follows the known distribution of PHF tau in the brain [76] where higher (18)F-T807 cortical retention was significantly associated with increasing disease severity, consistent with post…”
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 1×
“[49] Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM.”
Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · cited 1×
“[24] Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al.”
Baugh, C. M., Stamm, J. M., Riley, D. O., Gavett, B. E., Shenton, M. E., Lin, A., Nowinski, C. J., Cantu, R. C., McKee, A. C., & Stern, R. A. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9164-5 · Cited by 486 · cited 2×
“[15] Baugh CM, Stamm JM, Riley DO, Gavett BE, Shenton ME, Lin A,”
Mutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438 · cited 2×
“Published b 16/j.jalz.2014.04.013 dementia with parkinsonism linked to chromosome-17 (FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE) [1–5].”
InfluentialZhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300 · cited 2×
“[60] Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, et al.”
Structural Principles of Tau and the Paired Helical Filaments of Alzheimer's Disease
Mandelkow, E., Von Bergen, M., Biernat, J., & Mandelkow, E. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00053.x · Cited by 243 · cited 2×
“[13] Mandelkow E, von Bergen M, Biernat J, Mandelkow EM.”
Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226 · cited 1×
“The hyperphosphorylation of tau leads to weaker microtubule binding [55] and an increase of unbound phospho-tau concentration in the cytosol.”
A highly selective and specific PET tracer for imaging of tau pathologies
Zhang, W., Arteaga, J., Cashion, D. K., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120712 · Cited by 195
Delaère, P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F., & Hauw, J.-J. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90391-l · Cited by 186
Dickson, D. W. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00065-1 · Cited by 168
Amyloid Imaging With Carbon 11–Labeled Pittsburgh Compound B for Traumatic Brain Injury
Hong, Y. T., Veenith, T., Dewar, D., Outtrim, J. G., Mani, V., Williams, C., Pimlott, S., Hutchinson, P. J. A., Tavares, A., Canales, R., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4847 · Cited by 158
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106 · cited 4×
“Published b 16/j.jalz.2014.04.013 dementia with parkinsonism linked to chromosome-17 (FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE) [1–5].”
InfluentialDuyckaerts, C., Brion, J. P., Hauw, J. J., & Flament-Durand, J. (1987) · Acta Neuropathologica · doi:10.1007/bf00693783 · Cited by 89 · cited 1×
“[27] Duyckaerts C, Brion JP, Hauw JJ, Flament-Durand J.”
Cited by
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501
Self-citationSchwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
“The recent development of candidate PET imaging tracers targeting aggregated tau (Chien et al., 2013; Maruyama et al., 2013; Okamura et al., 2014; Villemagne and Okamura, 2014) now enables not only the brain burden but also the anatomical distribution of tau pathology to be mapped directly in living subjects.”
BackgroundThe complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 309
Metadata
- Authors
- Villemagne, V. L., & Okamura, N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-06
- Volume
- 10
- Issue
- 3S
- Pages
- S254-64
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2059516728
- Cited by
- 96
- References
- 34
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.